Skip to content

Author

C. Riff

We have 2 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody.

These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.

E. L, C. Riff, Antonio DiGiandomenico et al. · 0 citations
Open access Oct 2026

Absorption, distribution, metabolism and excretion of londamocitinib after single-dose inhaled, intravenous and oral administration in healthy participants.

Following inhaled and oral dosing, londamocitinib demonstrated rapid absorption, and faecal excretion as the principal route of elimination and exhibited an acceptable safety and tolerability profile.

C. Riff, Peter Bold, M. Heijer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.